Varona Adolfo, Blanco Lorena, López José I, Gil Javier, Agirregoitia Ekaitz, Irazusta Jon, Larrinaga Gorka
Dept. of Physiology, Faculty of Medicine and Dentistry, Hospital de Basurto, University of the Basque Country, E-48080 Bilbao, Bizkaia, Spain.
Am J Physiol Renal Physiol. 2007 Feb;292(2):F780-8. doi: 10.1152/ajprenal.00148.2006. Epub 2006 Sep 19.
Peptides play important roles in cell regulation and signaling in many tissues and are regulated by peptidases, most of which are highly expressed in the kidney. Several peptide convertases have a function in different tumor stages, and some have been clearly characterized as diagnostic and prognostic markers for solid tumors, including renal cancer; however, little is known about their in vivo role in kidney tumors. The present study compares the activity of a range of peptidases in human tumor samples and nontumor tissue obtained from clear cell renal cell carcinoma (CCRCC) patients. To cover the complete spectrum and subcellular distribution of peptide-converting activity, acid, neutral, basic, and omega activities were selected. CCRCC displays a selective and restricted pattern of peptidase activities. Puromycin-sensitive aminopeptidase activity in the tumor increases [tumor (t) = 10,775 vs. nontumor (n) = 7,635 units of peptidase (UP)/mg protein; P < 0.05], whereas aminopeptidase N decreases (t = 6,664 vs. n = 33,381 UP/mg protein; P < 0.001). Aminopeptidase B activity of the particulate fraction in tumors decreases (t = 2,399 vs. n = 13,536 UP/mg protein; P < 0.001) compared with nontumor tissues, and aspartyl-aminopeptidase activity decreases significantly in CCRCC (t = 137 vs. n = 223 UP/mg protein; P < 0.05). Soluble and particulate pyroglutamyl peptidase I activities, aminopeptidase A activity, and soluble aminopeptidase B activity do not vary in renal cancer. The relative expression for the aforementioned peptidases, assayed using quantitative RT-PCR, increases in CCRCC for aminopeptidases B (1.5-fold) and A (19-fold), aspartyl-aminopeptidase (3.9-fold), puromycin-sensitive aminopeptidase (2.5-fold), and pyroglutamyl peptidase I (7.6-fold). Only aminopeptidase N expression decreases in tumors (1.3-fold). This peptidase activity profile in the neoplastic kidney suggests a specific role for the studied convertases and the possible involvement of an intracrine renin-angiotensin system in the pathogenesis of CCRCC.
肽在许多组织的细胞调节和信号传导中发挥重要作用,并受肽酶调节,其中大多数肽酶在肾脏中高度表达。几种肽转化酶在不同肿瘤阶段发挥作用,一些已被明确表征为实体瘤(包括肾癌)的诊断和预后标志物;然而,它们在肾肿瘤中的体内作用知之甚少。本研究比较了从透明细胞肾细胞癌(CCRCC)患者获得的一系列肽酶在人肿瘤样本和非肿瘤组织中的活性。为了涵盖肽转化活性的完整范围和亚细胞分布,选择了酸性、中性、碱性和ω活性。CCRCC表现出肽酶活性的选择性和受限模式。肿瘤中嘌呤霉素敏感氨肽酶活性增加[肿瘤(t)=10,775与非肿瘤(n)=7,635肽酶单位(UP)/mg蛋白质;P<0.05],而氨肽酶N活性降低(t=6,664与n=33,381 UP/mg蛋白质;P<0.001)。与非肿瘤组织相比,肿瘤中颗粒部分的氨肽酶B活性降低(t=2,399与n=13,536 UP/mg蛋白质;P<0.001),并且天冬氨酰氨肽酶活性在CCRCC中显著降低(t=137与n=223 UP/mg蛋白质;P<0.05)。可溶性和颗粒性焦谷氨酸肽酶I活性、氨肽酶A活性和可溶性氨肽酶B活性在肾癌中无变化。使用定量RT-PCR测定的上述肽酶的相对表达在CCRCC中,氨肽酶B(增加1.5倍)、氨肽酶A(增加19倍)、天冬氨酰氨肽酶(增加3.9倍)、嘌呤霉素敏感氨肽酶(增加2.5倍)和焦谷氨酸肽酶I(增加7.6倍)均增加。只有肿瘤中的氨肽酶N表达降低(降低1.3倍)。肿瘤肾脏中的这种肽酶活性谱表明所研究的转化酶具有特定作用,并且内分泌肾素-血管紧张素系统可能参与CCRCC的发病机制。